Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human

Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human Int Ophthalmol (2018) 38:1021–1025 https://doi.org/10.1007/s10792-017-0553-z ORIGINAL PAPER Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human . . . . Ugur Acar Bekir Kucuk Mehmet Koray Sevinc Seckin Aykas Mesut Erdurmus Gungor Sobaci Received: 12 October 2016 / Accepted: 10 May 2017 / Published online: 19 May 2017 Springer Science+Business Media Dordrecht 2017 Abstract Results The mean age of the patients was Aim To evaluate the whether intravitreal erythropoi- 52.38 ± 12.00 years; 2 (12.50%) of them were etin (EPO) administration has any beneficial or female, and 14 (87.50%) of them were male. The adverse effect in patients with late-stage optic neu- mean BCVA levels of 16 patients with optic atrophy ropathy (ON) or not. were 1.12 ± 0.25 logMAR at the initial examination Methods The study examined 16 eyes of 16 patients and 1.08 ± 0.26 logMAR at the final visit who had late-stage ON and C1/20 best-corrected (p = 0.102). There was no statistically significant visual acuity (BCVA) in their affected eye. There were difference between the initial and final RNFL thick- nonarteritic ischemic ON in 10 (62.5%) eyes, trau- nesses, IOP values, p-ERG or p-VEP responses. matic ON in 4 (25.0%) eyes and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Ophthalmology Springer Journals

Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human

Loading next page...
 
/lp/springer_journal/intravitreal-erythropoietin-injection-in-late-stage-optic-neuropathy-a-rTis0pzm07
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media Dordrecht
Subject
Medicine & Public Health; Ophthalmology
ISSN
0165-5701
eISSN
1573-2630
D.O.I.
10.1007/s10792-017-0553-z
Publisher site
See Article on Publisher Site

Abstract

Int Ophthalmol (2018) 38:1021–1025 https://doi.org/10.1007/s10792-017-0553-z ORIGINAL PAPER Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human . . . . Ugur Acar Bekir Kucuk Mehmet Koray Sevinc Seckin Aykas Mesut Erdurmus Gungor Sobaci Received: 12 October 2016 / Accepted: 10 May 2017 / Published online: 19 May 2017 Springer Science+Business Media Dordrecht 2017 Abstract Results The mean age of the patients was Aim To evaluate the whether intravitreal erythropoi- 52.38 ± 12.00 years; 2 (12.50%) of them were etin (EPO) administration has any beneficial or female, and 14 (87.50%) of them were male. The adverse effect in patients with late-stage optic neu- mean BCVA levels of 16 patients with optic atrophy ropathy (ON) or not. were 1.12 ± 0.25 logMAR at the initial examination Methods The study examined 16 eyes of 16 patients and 1.08 ± 0.26 logMAR at the final visit who had late-stage ON and C1/20 best-corrected (p = 0.102). There was no statistically significant visual acuity (BCVA) in their affected eye. There were difference between the initial and final RNFL thick- nonarteritic ischemic ON in 10 (62.5%) eyes, trau- nesses, IOP values, p-ERG or p-VEP responses. matic ON in 4 (25.0%) eyes and

Journal

International OphthalmologySpringer Journals

Published: May 19, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off